Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review

Katharina Abraham (), Isaac Corro Ramos, C. Louwrens Braal, Talitha Feenstra, Anne Kleijburg, George A. K. Voorn and Carin Uyl- de Groot
Additional contact information
Katharina Abraham: Erasmus University Rotterdam (EUR), Erasmus School of Health Policy and Management
Isaac Corro Ramos: EUR
C. Louwrens Braal: Erasmus University MC Cancer Institute
Talitha Feenstra: University of Groningen, Groningen Research Institute of Pharmacy
Anne Kleijburg: CAPHRI Care and Public Health Research Institute, Maastricht University
George A. K. Voorn: Wageningen University and Research
Carin Uyl- de Groot: Erasmus School of Health Policy and Management, EUR

PharmacoEconomics, 2025, vol. 43, issue 8, No 2, 849-858

Abstract: Abstract Objective In this study we aimed to identify possible changes over time in validation efforts and the way in which they are reported for model-based health economic (HE) evaluations, given the introduction of several new validation tools and methods in the past decade. Methods A systematic review was conducted using PubMed and Embase on published HE models for early breast cancer (EBC) for the period 2016 to 2024. AdViSHE—consisting of four validation categories that cover the main HE model aspects—was utilized to systematically evaluate the reported evaluation efforts. The percentage of studies reporting validation per category was compared with the review by de Boer et al. that covers the years 2008 to 2015. Results Of the 2199 records, 78 studies fulfilled the eligibility criteria. Reported validation efforts did not significantly improve compared with the previous period, except for the validation of input data by experts. Reporting on the validation of the conceptual model remained low with around 10% of the studies providing validation. Validation of the computerized model and validation against outcomes using alternative input data were the most underreported validation categories with

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-025-01491-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:8:d:10.1007_s40273-025-01491-2

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-025-01491-2

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().